SPONSORED

 

A Major Dr-ug Discovery Could Be Game-Changing for the Potential $245 Billion Weight Management Market(1)

NeonMind Biosciences May Have Unearthed “Nature’s Own Appetite Suppressant” for Millions Considered Overweight or Obese(2)

Canada CSE: (NEON) United States OTC: (NMDBF)

November 23, 2021:

NeonMind Announces Successful Completion of Pre-IND Consultation with FDA on Clinical Path for Obesity Drug Candidate NEO-001

The obesity issue in the U.S is out of control.

Consider some of these stats:(3)

  • Nearly one out of every three adults could be obese, according to a Harvard study.
  • About 18.5% of children, some as young as two years old, are considered obese.
  • It costs U.S. taxpayers nearly $150 billion per year to fight obesity issues.

But wait, it gets worse.

Right now, obesity may account for approximately 37% of the global burden of disease.(4)

By 2030, about 20% of the global population could also be obese, according to the National Centers for Biotechnology Information. In addition, obesity is linked to more than 60 chronic diseases, including  type 2 diabetes, heart disease, stroke, and cancer.(3)

In short, the world may be eating itself to an early grave.

However, according to NeonMind Biosciences Canada CSE: (NEON) United States OTC: (NMDBF), help could be on the way in the form of psi-lo-cybin, which could potentially revolutionize the weight loss market, and help millions shed unwanted weight.

After all, psi-lo-cybin activates serotonin receptors, or “nature’s own appetite suppressant,” as noted by Psychology Today. “This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight.”(2)

The Top Reasons to Consider NeonMind Biosciences Canada CSE: (NEON) United States OTC: (NMDBF)

  1. Psi-lo-cybin could potentially revolutionize treatment in the potential $245.5 billion weight loss market, and may activate serotonin receptors that can curb cravings, shut off appetite, reduce eating, and cause weight loss.(1)
  2. Health Canada approved NeonMind’s preclinical psi-lo-cybin trials as a potential treatment for weight loss and food addiction.(5)
  3. NeonMind commenced its pre-clinical trials in 2020 and plans to have enough data for its scheduled Phase 2 human clinical trials in early 2021. To date, a completed pre-clinical study demonstrated weight sparing clinical signal for low and high-dose psi-lo-cybin regime.(1)
  4. If successful, NeonMind could have potential access to approximately 1.9 billion people who are currently overweight or obese.(1)
  5. NeonMind is uniquely positioned in the psych-e-delics market.  It’s one of two companies currently working on developing psi-lo-cybin into a prescription dr-ug for weight management.(1)
  6. Its patent portfolio provides protection for therapeutic use of psi-lo-cybin and derivatives for weight management.(1)
  7. NeonMind completed a supply agreement with Psygen Labs for psi-lo-cybin for clinical studies.(6)
  8. NeonMind also has a solid management team with significant experience in dr-ug development and commercialization, and has extensive U.S. and international patents pending for a spectrum of weight management conditions.
  9. NeonMInd has multiple anticipated milestones for 2021, including the engagement of expert integrated dr-ug development organization, preclinical study #2: data expected 2Q21, Phase 2 study design and first patient enrolled 4Q21, dietary supplement launch in US 2Q21, natural health products launch in Canada 3Q21, the expansion of current IP portfolio, and a pre-IND meeting with FDA 4Q21.(1)

Just Who is NeonMind Biosciences Canada CSE: (NEON) United States OTC: (NMDBF)?

At the moment, NeonMind Biosciences, has two dr-ug development candidates exploring psi-lo-cybin as an innovative treatment approach to treat obesity and support weight loss.

NeonMind’s first dr-ug candidate employs psi-lo-cybin as an agonist to the serotonin receptor 5-HT2A, which is involved in the hallucinogenic effect of psych-e-delics.  The second dr-ug candidate employs psi-lo-cybin as an agonist to the serotonin 5-HT2C receptor, which controls appetite.

The company is also working with Dr. C. Laird Birmingham, a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at the University of British Columbia.  He’ll consult with the company to develop protocols for its Phase 2 Clinical Trial administering psi-lo-cybin to treat obese patients.(7)

NeonMind also just engaged Certara, the global leader in model-informed dr-ug development to provide strategic integrated dr-ug development support for the investigation of NeonMind’s psi-lo-cybin based dr-ug candidates for the treatment of obesity.(8)

NeonMind Biosciences Canada CSE: (NEON) United States OTC: (NMDBF)– Already Seeing Significant Success

For one, the company’s proprietary animal data supports psi-lo-cybin efficacy in reducing weight gain.

Two, weight reduction has been seen in a short period of time.(1)

Three, the novel data strengthens patent applications.

From here, the company has key anticipated milestones for the year.(1)

  • Engagement of expert integrated dr-ug development organization
  • Preclinical study #2: data expected 2Q21
  • Phase 2 study design and first patient enrolled 4Q21
  • Dietary Supplement launch in US 2Q21
  • Natural Health Products launch in Canada 3Q21
  • Expand current IP portfolio
  • Pre-IND meeting with FDA 4Q21

Plus, as NeonMind President and CEO Rob Tessarolo notes: 

“It is a very exciting time to be in the psych-e-delics industry, which is undergoing rapid expansion. There is a continuous flow of new companies entering the market and each is replete with important research ideas and vying for the conditions necessary to drive growth.  The growing interest in studying psych-e-delic substances coupled with a fresh look from regulatory agencies means some of these substances have the potential to make it to market and help those patients who need innovative new approaches in care. We have established a distinctive focus on developing innovative treatment modalities for people dealing with obesity.”(9)

“Psych-e-delic therapy has the potential to institute long term positive behaviors that may impact food intake and other lifestyle changes which affect weight management, and psi-lo-cybin in low doses may help control appetite and satiety. This important element sets us apart from numerous other psych-e-delic companies working to advance research ideas in psych-e-delic.”(9)

Is There a Good Deal of Support for Psych-e-delic Treatments?

Look at the evidence. It doesn’t lie.

  • The US FDA appears to be supportive of psi-lo-cybin research. In 2019, for example, the agency recognized psi-lo-cybin as a potentially “breakthrough therapy” for depression.(10)
  • As noted by NPR, a study from JAMA Psychiatry recently found that psi-lo-cybin “worked better than the usual antidepressant medications.”(11)
  • Johns Hopkins Medicine launched the Center for Psych-e-delic and Consciousness Research to study how compounds like LS and psi-lo-cybin could potentially treat mental health problems such as anorexia, addiction and depression.(12)
  • A study in the journal, Nature said that “Psi-lo-cybin for treatment-resistant depression: fMRI-measured brain mechanisms” – showed that around 47% of patients with treatment-resistant-depression showed positive responses approximately five weeks after psi-lo-cybin treatments.”(13)
  • State and local governments are also beginning to accept its usage as well. In fact, Oregon just became the first state to officially decriminalize the possession of psych-e-delics, joining Denver, Oakland, and Santa Cruz’s decisions on psi-lo-cybin.(14)

However, This is Just a Fraction of the NeonMind Growth Story 

NeonMind is also commercializing mush-room-infused food products- including products infused with Lion’s Mane, Turkey Tail, Reishi and Cordyceps.

Additionally, the company launched a coffee eCommerce platform in November 2020 with infused coffees.

This platform has immense potential, because people are reportedly craving infused coffees and teas for an “added superfood go-to morning beverage,” according to Yahoo Life.

“Mush-rooms have long been used in Chinese medicine and newer research shows they are the highest dietary source of the antioxidants ergothioneine and glutathione, which help protect the body against the type of damage that can eventually contribute to age-related diseases like cancer, heart disease, Parkinson’s and Alzheimer’s,” says Beth Warren, RDN, author of Secrets of a Kosher Girl. “Mush-room coffees and teas can give anyone a boost, but they may be especially beneficial for those who are dealing with chronic diseases and inflammation.”(15)

Some of the products being offered by NeonMind include:(16)

INSTANT COFFEES

  • Rest Blend — A well-balanced coffee infused with Lion’s Mane and Reishi mush-rooms, as well as Ashwagandha and Turmeric.
  • Energize Blend — Robust coffee infused with Turkey Tail and Cordycep mush-rooms, blended with Holy Basil and Moringa.

BREWED COFFEES

  • Focus Blend – Dark Roast — A well-balanced coffee infused with Lion’s Mane and Reishi mush-rooms, combined with Gotu Kola and Brahmi.
  • Protect Blend – Medium Roast — A robust coffee infused with Turkey Tail and Cordycep mush-rooms, blended with the Moringa and Amla Berry.

NeonMind Biosciences Canada CSE: (NEON) United States OTC: (NMDBF): Strong Leadership, Strong Results  

Successful companies tend to possess common traits, and one of those traits is a strong management team. NeonMind Biosciences certainly has that covered well.

ROBERT TESSAROLO
PRESIDENT & CHIEF EXECUTIVE OFFICER

  • Over 25 years of experience in the pharmaceutical industry
  • Former President, CEO and Director of Mind Medicine Inc.

TREVOR MILLAR
CHIEF PSYCH-E-DELIC OFFICER

  • Social-entrepreneur advancing the psych-e-delic movement since 2013
    Board Chairman Multidisciplinary Association of Psych-e-delic Studies (MAPS) Canada
    Co-Founder and Board Member Canadian Psych-e-delic Association.
  • Founder of Liberty Root Therapy Inc.; featured in the award-winning psych-e-delic documentary ‘DOSED’

RICK HUANG
CFO

  • CFO of Better Plant Sciences Inc. (CSE: PLNT)
    Serves as Chair of the Audit Committee for Datable
  • Technology Corp. (TSXV: TTM)
    Former CFO of Hanwei Energy Services Corp.
  • Former Chair of Governance and member of Audit
  • Committees at Poydras Gaming Finance Corp.
  • Former President & CEO of Cipher Pharmaceuticals Inc.
  • Former VP, General Manager Celgene US Inflammation & Immunology and former President Watson Pharmaceuticals Canada

PENNY WHITE
EXECUTIVE CHAIRMAN, DIRECTOR, FOUNDER

  • Serial entrepreneur with over two decades of experience building companies.
  • Recognized in PROFIT Magazine’s W100
  • Co-founder, President and CEO of Better Plant Sciences Inc.
  • Former Director Merus Labs Inc.

JEFF B. SMITH
INDEPENDENT DIRECTOR

  • Over 30 years of general management experience
  • Previously the Global Chief Transformation Officer at Johnson & Johnson Consumer Companies
  • Co-Founder and CEO of Paragon Vitamins and
    Co-Founder & Partner at Ignite Ventures Studios

KARI RICHARDSON
INDEPENDENT DIRECTOR

  • Over 15 years practicing as a securities lawyer
  • Partner of Owen Bird Law; practice focused on mergers
  • and acquisitions, corporate finance and securities.
    Member of the Law Society of New Brunswick since 1997 and a member of the Law Society of British Columbia since 2005.

WILLIAM PANENKA
CHAIR, SCIENTIFIC ADVISORY BOARD

  • Dually boarded Neurologist and Psychiatrist and Canadian Institute of Health Research funded academic faculty member at the University of British Columbia.
  • Founder and Director, Translational Life Sciences Inc.

LAIRD BIRMINGHAM
MEMBER, ADVISORY BOARD

  • World renowned eating disorder specialist for over 35 years, who has pioneered several new internationally recognized treatments for eating disorders
  • Professor at the University of British Columbia, Faculty of Medicine Department of Psychiatry

ALASDAIR BARR
PRINCIPAL INVESTIGATOR

  • PhD in Neuropharmacology, post-doctoral training at Scripps Institute and dr-ug discovery with Novartis.
  • Tenured Faculty member at the Department of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, UBC
  • Approved by Health Canada to possess psi-lo-cybin for NeonMind Preclinical trial

The Top Reasons to Consider NeonMind Biosciences Canada CSE: (NEON) United States OTC: (NMDBF)

  1. Psi-lo-cybin could potentially revolutionize treatment in the potential $245.5 billion weight loss market, and may activate serotonin receptors that can curb cravings, shut off appetite, reduce eating, and cause weight loss.(1)
  2. Health Canada approved NeonMind’s preclinical psi-lo-cybin trials as a potential treatment for weight loss and food addiction.(5)
  3. NeonMind commenced its pre-clinical trials in 2020 and plans to have enough data for its scheduled Phase 2 human clinical trials in early 2021. To date, a completed pre-clinical study demonstrated weight sparing clinical signal for low and high-dose psi-lo-cybin regime.(1)
  4. If successful, NeonMind could have potential access to approximately 1.9 billion people who are currently overweight or obese.(1)
  5. NeonMind is uniquely positioned in the psych-e-delics market. It’s one of two companies currently working on developing psi-lo-cybin into a prescription dr-ug for weight management.(1)
  6. Its patent portfolio provides protection for therapeutic use of psi-lo-cybin and derivatives for weight management.(1)
  7. NeonMind completed a supply agreement with Psygen Labs for psi-lo-cybin for clinical studies.(6)
  8. NeonMind also has a solid management team with significant experience in dr-ug development and commercialization, and has extensive U.S. and international patents pending for a spectrum of weight management conditions.
  9. NeonMInd has multiple anticipated milestones for 2021, including the engagement of expert integrated dr-ug development organization, preclinical study #2: data expected 2Q21, Phase 2 study design and first patient enrolled 4Q21, dietary supplement launch in US 2Q21, natural health products launch in Canada 3Q21, the expansion of current IP portfolio, and a pre-IND meeting with FDA 4Q21.(1)
Source 1: https://neonmindbiosciences.com/wp-content/uploads/investors/NeonMind_Investor.pdf
Source 2: https://www.psychologytoday.com/us/blog/the-antidepressant-diet/201008/serotonin-what-it-is-and-why-its-important-weight-loss
Source 3: https://www.singlecare.com/blog/news/obesity-statistics/
Source 4: https://neonmindbiosciences.com
Source 5: https://bit.ly/3fhbRYJ
Source 6: https://money.yahoo.com/better-plant-sciences-subsidiary-neonmind-070000231.html
Source 7: https://bit.ly/3rr9ANh
Source 8: https://currently.att.yahoo.com/att/neonmind-engages-certara-advance-synthetic-110000514.html
Source 9: https://bit.ly/3ddFDLi
Source 10: https://bit.ly/3w3YsZV
Source 11: https://n.pr/31kO5TJ
Source 12: https://bit.ly/3fiSAX8
Source 13: https://www.nature.com/articles/s41598-017-13282-7
Source 14: https://bit.ly/31o8KWY
Source 15: https://coffeetalk.com/daily-dose/for-roasters-retailers/10-2020/70095/
Source 16: https://neonmind.com/